Clinical Trial Update: Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) [Phase 3]

View source ↗

Summary

Phase 3 trial update for bapineuzumab in mild-to-moderate Alzheimer's disease, focusing on ApoE4 non-carriers. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Bapineuzumab (bapineuzumab)

Snippet

Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC | Conditions: Alzheimer's Disease | Phase 3 | Status: COMPLETED